MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Thursday, January 1, 2015

Slideshow: Looking Good and Feeling Good With MS

Take time every day to slather your favorite lotion all over your body, especially on your legs, hands, and feet. It doesn't have to cost a fortune. Drugstores sell many moisturizers for under $10. Splurging? Try massage. Along with relaxing your muscles and helping your circulation, it feels good. Studies show it can boost mood and improve self-esteem for people with MS.

Watch the slideshow by clicking here

 Keep CURRENT with MS Views and News - OPT-IN here


5 Things Your Loved One Isn’t Telling You About MS

By Camille Noe Pagán
WebMD Medical Reference
Reviewed by Neil Lava, MD
If you have a significant other, friend, or relative with multiple sclerosis(MS), you might know about some of the physical problems that can come with the disease. But chances are, that’s only part of what your loved one deals with. 
MS can cause invisible symptoms that can be tricky to talk about.
Here are five common problems that many people with MS face, though they might never tell you.
“I can’t stand it when people say, 'I’m tired, too.'"
For people with MS, fatigue is a regular part of life. Trouble is, “lots of people think that just means I’m tired,” says Ann Pietrangelo, a 55-year-old MS Foundation ambassador and writer who lives in Williamsburg, VA. “They’ll say, 'Oh, yeah, I know exactly what you mean -- I didn’t get enough sleep last night.' They don’t understand that a nap or good night’s sleep is not going to fix the exhaustion that comes with MS.”
While your loved one might feel fine sometimes, “it’s not uncommon for a person with MS to wake up and take a shower, and that’s about all they can do for the day,” says Karen Blitz-Shabbir, DO. She's the director of the North Shore/LIJ  MS Care Center in Long Island, NY.
Even if their physical energy is up, “brain fog can cause mental fatigue, which makes it hard to get a lot done,” says Matthew McCoyd, MD. He's a neurologist at Loyola University Medical Center in Illinois.
Be supportive by saying “I’m sorry” or “Can I help you?” rather than sharing how tired you’re feeling.
“I wish you’d ask my spouse if she needs help.”
Something people with MS hear a lot is, “Let me know if you need help.” While specific offers, like “I’m going to the grocery store. Is there anything I can pick up for you?” can be helpful, consider asking the person’s partner, too.

 Keep CURRENT with MS Views and News - OPT-IN here


'Immune Reset' Effective Against MS Short Term

Some 90% of patients with relapsing-remitting multiple sclerosis had no clinical relapses or signs of progression 3 years after receiving high-dose immunosuppression followed by autologous hematopoietic stem-cell transplant, researchers reported.

Interim results from 25 participants in the closely watched HALT-MS trial yielded a progression-free survival rate of 90.9% (95% CI 73.7%-97.1%) and a relapse-free survival rate of 86.3% (95% CIO 68.1%-94.5%), according to Richard A. Nash, MD, of the Colorado Blood Institute in Denver, and colleagues.

Most serious adverse events occurred within the first month after starting the myeloablative regimen, but nine patients experienced grade 3 events and one suffered a grade 4 event after year two of the study, Nash and colleagues reported online in JAMA Neurology. Another patient died during study year three from MS progression-related causes, they noted.

These late adverse effects led two independent experts, writing an accompanying editorial, to caution that hematopoietic stem-cell transplant remained unproven as an MS treatment.

"The jury is still out regarding the appropriateness and indications of HCT [hematopoietic cell transplant] for MS," wrote M. Mateo Paz Soldan, MD, PhD, of the University of Utah in Salt Lake City, and Brian G.Weinshenker, MD, of the Mayo Clinic in Rochester, Minn.

In addition to their concerns about the treatment's safety, the editorialists also questioned the extent to which the desired "immune reset" had actually been achieved, given that new and/or enlarging brain lesions continued to develop and clinical relapses occurred in some patients more than 3 years post-transplant.

"This study raises concern that those endpoints [freedom from clinical or radiological relapse] have not been adequately achieved," Paz Soldan and Weinshenker wrote.

But Nash and colleagues portrayed the results as a win for HCT, albeit with caveats about the study duration so far and the need for additional confirmatory trials. The study did not have a control group.

Study Details

The investigators noted that HCT has been tested in MS before, with ambiguous results, probably because patients tended to have advanced disease and therefore continued to show functional declines related to non-inflammatory neurodegeneration. HCT is not regenerative, but rather is intended to terminate the immunologically mediated demyelination that sets the stage for, but is not directly causative of the subsequent neuronal and functional loss.

Read more

 Keep CURRENT with MS Views and News - OPT-IN here


IMPACT of MS on the Family


Device is designed to help resuscitate a choking victim

SARASOTA, Fla. -- Choking is the third leading cause of accidental death in the over 65 population and the forth leading cause of accidental death in the United States.

For those with Multiple Sclerosis in particular, including early on in the course of the disease, dysphagia (difficulty swallowing), pulmonary dysfunction and muscle weakness arise. When these impairments occur early on most are unaware that there is a problem.

Dysphagia may cause the individual to cough after drinking liquids or choke when eating certain foods, especially those with a crumbly texture.
Whether you live with MS or are a caregiver for someone living with it, you can empathize with the array of swallowing challenges and the subsequent psychological toll that it creates for all.
Unfortunately, if the swallowing challenges turn into a choking episode, there is a chance the individual may aspirate, or inhale fluid or solids into the upper respiratory tract, resulting in aspiration pneumonia.
Finally, there is a device to help with this life-threatening issue: LifeVac; a revolutionary new product designed to remove an object from an obstructed airway.
The LifeVac is a non-powered single patient portable suction apparatus developed for resuscitating a choking victim when standard ACLS protocol has failed. The negative pressure generated by the force of the suction is 3 times greater than the highest recorded choke pressure. The duration of suction is minimal so LifeVac is safe and effective.
Also you can watch a YouTube video on this found here


LifeVac is designed with a patented valve to prevent any air from exiting through the mask. This patented designed valve prevents air from pushing food or objects downward. This creates a one-way suction to remove the lodged food or object.
No prescription required.

LifeVac can be purchased online at and at these Medical Department Stores in Florida: 
Sarasota 3672 Webber Street  941.556.3041 / Venice 1180 Jacaranda Blvd. 941.497.2273   /
Port Charlotte 4265 Tamiami Trail 941.743.6644

Neither Stu's Views and MS News or MS Views and News endorses any product shown on this blog. Please always consult with your healthcare provider first, before acquiring a product


Tuesday, December 30, 2014

MS Views and News seeks a Grant Writer/Admin Ass't

MS Views and News seeks a Grant Writer/Admin Ass't

Not for profit seeks a grant writer-general assistant, for growing Multiple Sclerosis patient advocacy organization.

MS Views and News provides education and information for the global Multiple Sclerosis community via the internet and live seminars.

Skills Needed: Strong writing ability, organization and the ability to work independently and with a team.

Please Contact:    



Monday, December 29, 2014

Cognitive Study in MS Highlighted Among Most Important of 2014

December 23, 2014
The Editorial Board of Neurology Today, a journal of the American Academy of Neurology, selected a study about cognition and MS among the most important studies published in 2014, suggesting the need for earlier rehabilitation for people with MS who experience cognitive problems. Read more from Neurology Today.
Read more about MS research progress made in 2014.

 Keep CURRENT with MS Views and News - OPT-IN here


Immunosuppressive Therapy and Stem Cell Study for Multiple Sclerosis

2014-12-29 17:45
immunosuppressive therapy multiple sclerosis
Investigators have just released the interim results of a five-year study of high-dose immunosuppressive therapy (HDIT) and hematopoietic stem cell therapy in 24 individuals with multiple sclerosis. After three years, most of the participants showed improvements in neurological function and sustained remission of active relapsing-remitting MS (RRMS).
The new JAMA Neurology article reports the findings of the Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) study. Basically, the idea is that use of HDIT supported by autologous (use of a patient’s own cells) hematopoietic stem cell infusions (transplantation) will stop disease activity in individuals who have poor prognosis RRMS.
In this study, autologous hematopoietic cell transplantation involved removing CD34 stem cells and storing them while the individuals were treated with high-dose immunosuppressive therapy; that is, the chemotherapy drugs carmustine, cytarabine, etoposide, and melphalan. The stored hematopoietic stem cells, which are responsible for the formation of blood, were then transfused into the patient’s bloodstream
At the three-year evaluation point, the authors found that, without the use of any maintenance therapy:
  • Overall rate of event-free survival (i.e., survival without loss of neurologic function, new lesions seen on imaging, or clinical relapse) was 78.4 percent
  • Progression-free survival was 90.9 percent
  • Clinical relapse-free survival was 86.3 percent
  • Quality of life, functional scores, and neurological disability all also improved
The authors concluded that the combination of high-dose immunosuppressive therapy and hematopoietic stem cell transplantation “may represent a potential therapeutic option for patients with MS in whom conventional immunotherapy fails.” However, they also emphasized that “longer follow-up is needed to determine the durability of the response.”
This combination therapeutic approach is not without side effects. The most common adverse events were cytopenias (64%), infections (56%), gastrointestinal disorders (36%), metabolism disorders (32%), and nervous system issues (24%), such as headache.

 Keep CURRENT with MS Views and News - OPT-IN here


a CME program for : Assessing Patient Adherence in MS:

MS leaders e-mail logo header

Program provided by MS-Leaders

Dear MS-Leaders Registrant,

Can you correctly answer this question:

All of the following are INDIRECT measurements that can be used to evaluate adherence to disease-modifying therapy, EXCEPT for:

A. Detection of the drug in blood or urine
B. Patient self-reports
C. Prescription claims data
D. Electronic medication monitors

Participate in our Clinical Dialogue and eCase Challenge to learn the answer to this and other questions related to MS therapy.


Rutgers, The State University of New Jersey and Medical Logix, LLC, are currently offering this educational program certified for CME and CE credit, at no charge to participants:

Release Date: July 14, 2014
Expiration Date: July 14, 2015

This enduring material has been approved for
AMA PRA Category 1 Credits™ and ANCC contact hours.

Supported by educational grants from
Genzyme, a Sanofi Company and Teva Pharmaceuticals

Jointly Provided by The Center for Continuing and Outreach Education
at Rutgers Biomedical and Health Sciences and Medical Logix, LLC

For additional information and to view the activity, please CLICK HERE 

Please keep in mind that you will need to login with your email address and password to access this program. If you forgot your password, click on the "Forgot Password" link in the top right corner of the site.

We hope you enjoy this informative educational program!

The MS-Leaders Team

The Center for Continuing and Outreach Education at
Rutgers Biomedical and Health Sciences
 30 Bergen Street ADMC7, Newark, NJ 07101-1709

Please do not respond to this email directly. Any questions or concerns,

 Keep CURRENT with MS Views and News - OPT-IN here